Royce & Associates LP Increases Stake in Apyx Medical Co. (NASDAQ:APYX)

Royce & Associates LP grew its stake in shares of Apyx Medical Co. (NASDAQ:APYX) by 3.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,582,490 shares of the company’s stock after buying an additional 85,267 shares during the period. Royce & Associates LP owned 0.07% of Apyx Medical worth $3,202,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Kingsview Wealth Management LLC increased its holdings in Apyx Medical by 156.7% in the 1st quarter. Kingsview Wealth Management LLC now owns 31,028 shares of the company’s stock valued at $42,000 after acquiring an additional 18,943 shares during the last quarter. RPg Family Wealth Advisory LLC bought a new stake in shares of Apyx Medical in the second quarter worth about $101,000. Rathbones Group PLC lifted its position in shares of Apyx Medical by 148.0% in the second quarter. Rathbones Group PLC now owns 251,334 shares of the company’s stock worth $337,000 after buying an additional 150,000 shares in the last quarter. Private Advisor Group LLC boosted its stake in Apyx Medical by 3.9% during the third quarter. Private Advisor Group LLC now owns 322,321 shares of the company’s stock valued at $400,000 after buying an additional 12,180 shares during the last quarter. Finally, Commonwealth Equity Services LLC grew its holdings in Apyx Medical by 2.9% during the 2nd quarter. Commonwealth Equity Services LLC now owns 511,561 shares of the company’s stock valued at $685,000 after buying an additional 14,481 shares in the last quarter. Institutional investors own 55.33% of the company’s stock.

Apyx Medical Price Performance

Shares of Apyx Medical stock opened at $1.23 on Tuesday. The stock has a 50 day moving average price of $1.21 and a 200-day moving average price of $1.33. Apyx Medical Co. has a one year low of $0.97 and a one year high of $3.26. The stock has a market cap of $46.30 million, a price-to-earnings ratio of -1.57 and a beta of 1.21. The company has a debt-to-equity ratio of 3.03, a quick ratio of 4.45 and a current ratio of 5.46.

Apyx Medical (NASDAQ:APYX) last posted its quarterly earnings data on Friday, November 8th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01. The business had revenue of $11.49 million for the quarter, compared to analysts’ expectations of $11.66 million. Apyx Medical had a negative net margin of 58.59% and a negative return on equity of 137.98%. During the same quarter in the previous year, the business posted ($0.13) earnings per share. Equities analysts expect that Apyx Medical Co. will post -0.68 EPS for the current year.

Analysts Set New Price Targets

APYX has been the subject of a number of research reports. Craig Hallum upgraded Apyx Medical to a “strong-buy” rating in a research report on Thursday, October 24th. JMP Securities reiterated a “market perform” rating on shares of Apyx Medical in a research report on Monday, September 16th. Finally, BTIG Research began coverage on shares of Apyx Medical in a report on Thursday, October 17th. They issued a “neutral” rating on the stock.

About Apyx Medical

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures.